JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety

EP: 1.Intro and Welcomes

EP: 2.Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission

EP: 3.Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice

EP: 4.Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis

EP: 5.Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies

EP: 6.Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments

EP: 7.Achieving Low Disease Activity and Remission: Managing Patient Expectations

EP: 8.Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies

EP: 9.Advanced Treatment Options for RA: Exploring the Data

EP: 10.Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons

Now Viewing

EP: 11.JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety

EP: 12.JAK Inhibitor Selectivity and Dose-Related Toxicity

Video content above is prompted by the following:

Tumor necrosis factor inhibitors (TNFis) and Janus kinase inhibitors (JAKis) present with differing characteristics and mechanisms of action (MOA), both between the 2 classes and within each class.

• Multiple characteristics distinguish JAKis from TNFis. For example, JAKis are stable small molecule proteins with a short half-life whereas TNFis are heat-sensitive monoclonal antibodies with a long half-life. How do their differences affect administration, efficacy, and safety outcomes?
• The MOA within the TNFi class also varies. Etanercept binds both TNF-a and TNF-b with high affinity whereas infliximab, adalimumab, golimumab, and certolizumab-pegol bind to TNF-a with high affinity but not TNF-b. What implications are associated with these different binding activities